The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
E-cigarette maker Juul Labs Inc.'s sales have been halted on two websites in China, just days after it launched in the world's biggest tobacco market.Biotech and Pharmaceuticalsread more
Investors might be wary that gasoline prices will continue to rise, and are looking to take back profits by selling off shares.Retailread more
The Trump administration move on California's auto emissions standards would likely set up a fight between the White House and the state.Politicsread more
"I feel really confident that defense-minded CEOs, when they are on defense, they're going to come to" flexible offices and away from traditional leases, Knotel CEO Amol Sarva...Commercial Real Estateread more
Fanatics has hired Michener Chandlee, Nike's corporate audit and chief risk officer, to become its chief financial officer, succeeding Lauren Cooks Levitan, CNBC has learned.Retailread more
Merck reported better-than-expected quarterly revenue due to higher sales of its vaccines and cancer drug Keytruda, which won an early U.S. approval on Monday for use in previously untreated lung cancer patients.
Shares of Merck, which also raised its full-year profit and revenue forecasts, were up 1.23 percent at $61.50 in premarket trading on Tuesday.
The second-largest U.S. drugmaker is betting on Keytruda to boost earnings as expectations for the drug have been building since its success in treating selected untreated patients.
The approval from the U.S. Food and Drug Administration confirms Merck's leading position in the hot area of medicines that fight tumors by harnessing the body's immune system.
Annual sales of the drug are now expected to reach $8.1 billion in 2021, according to consensus forecasts compiled by Thomson Reuters.
Third-quarter sales of Keytruda, which is already approved to treat advanced melanoma and some forms of lung cancer, rose to $356 million from $159 million, slightly below the consensus estimate of $376 million, according to Evercore ISI.
Merck said the company's total sales increased 5 percent to $10.54 billion, above analysts' average estimate of $10.18 billion, according to Thomson Reuters I/B/E/S.
Sales for its Gardasil vaccine rose 38 percent to $860 million, well above Evercore's consensus estimate of $635.6 million.
Net income attributable to Merck rose to $2.18 billion, or 78 cents per share, for the third quarter ended Sept. 30, from $1.83 billion, or 64 cents per share, a year earlier.
Excluding items, the company earned $1.07 per share, beating the average estimate of 99 cents per share.
Merck said it has raised its full-year 2016 GAAP earnings to $2.02 to $2.09 per share from $1.98 to $2.08 per share. The full-year revenue range was also raised to $39.7 billion to $40.2 billion from $39.1 billion to $40.1 billion.
Up to Monday's close of $60.75, Merck's stock had risen 15 percent this year, compared with a 3.5 percent fall in the S&P 500 Healthcare index.